Quantcast

After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA


Shutterstock photo

The following companies are expected to repor t earnings after hours on 03/11/2019. Visit our Earnings Calendar for a full list of expected earnings releases.



ADT Inc. ( ADT ) is reporting for the quarter ending December 31, 2018. The protection safety company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.11. This value represents a 283.33% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ADT is 10.25 vs. an industry ratio of 10.50.

Coupa Software Incorporated ( COUP ) is reporting for the quarter ending January 31, 2019. The internet software company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.26. This value represents a 85.71% decrease compared to the same quarter last year. In the past year COUP has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 53.33%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for COUP is -125.82 vs. an industry ratio of 10.10.

Stitch Fix, Inc. ( SFIX ) is reporting for the quarter ending January 31, 2019. The retail (shoe) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.05. This value represents a 28.57% decrease compared to the same quarter last year. In the past year SFIX has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 233.33%. The "days to cover" for this stock exceeds 14 days. Zacks Investment Research reports that the 2019 Price to Earnings ratio for SFIX is 160.63 vs. an industry ratio of 16.60, implying that they will have a higher earnings growth than their competitors in the same industry.

Dicerna Pharmaceuticals, Inc. ( DRNA ) is reporting for the quarter ending December 31, 2018. The biomedical (gene) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.23. This value represents a 74.44% increase compared to the same quarter last year. The "days to cover" for this stock exceeds 19 days. Zacks Investment Research reports that the 2018 Price to Earnings ratio for DRNA is -9.50 vs. an industry ratio of 19.10.

American Vanguard Corporation ( AVD ) is reporting for the quarter ending December 31, 2018. The chemical company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.23. This value represents a 35.29% increase compared to the same quarter last year. In the past year AVD has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2018 Price to Earnings ratio for AVD is 23.32 vs. an industry ratio of 11.70, implying that they will have a higher earnings growth than their competitors in the same industry.

PetIQ, Inc. ( PETQ ) is reporting for the quarter ending December 31, 2018. The medical products company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.07. This value represents a 63.16% decrease compared to the same quarter last year. In the past year PETQ and beat the expectations the other three quarters. The "days to cover" for this stock exceeds 22 days. Zacks Investment Research reports that the 2018 Price to Earnings ratio for PETQ is 34.38 vs. an industry ratio of 12.20, implying that they will have a higher earnings growth than their competitors in the same industry.

ChemoCentryx, Inc. ( CCXI ) is reporting for the quarter ending December 31, 2018. The drug company's consensus earnings per share forecast from the 5 analysts that follow the stock is $-0.27. This value represents a 133.75% decrease compared to the same quarter last year. CCXI missed the consensus earnings per share in the 2nd calendar quarter of 2018 by -27.27%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for CCXI is -12.21 vs. an industry ratio of -0.80.

Luxfer Holdings PLC ( LXFR ) is reporting for the quarter ending December 31, 2018. The machinery company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.31. This value represents a 63.16% increase compared to the same quarter last year. LXFR missed the consensus earnings per share in the 4th calendar quarter of 2017 by -24%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for LXFR is 10.76 vs. an industry ratio of 16.40.

Mistras Group Inc ( MG ) is reporting for the quarter ending December 31, 2018. The electrical instrument company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.21. This value represents a 40.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for MG is 24.02 vs. an industry ratio of 14.20, implying that they will have a higher earnings growth than their competitors in the same industry.

Oxford Immunotec Global PLC ( OXFD ) is reporting for the quarter ending December 31, 2018. The medical instruments company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.19. This value represents a 44.12% increase compared to the same quarter last year. The last two quarters OXFD had negative earnings surprises; the lates t report they missed by -140%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for OXFD is -14.46 vs. an industry ratio of 19.00.

Forterra, Inc. ( FRTA ) is reporting for the quarter ending December 31, 2018. The building company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.27. This value represents a 3.57% increase compared to the same quarter last year. The "days to cover" for this stock exceeds 49 days. Zacks Investment Research reports that the Price to Earnings ratio for FRTA is 0.00 vs. an industry ratio of 17.60.

Kala Pharmaceuticals, Inc. ( KALA ) is reporting for the quarter ending December 31, 2018. The biomedical (gene) company's consensus earnings per share forecast from the 5 analysts that follow the stock is $-0.52. This value represents a 13.04% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for KALA is -3.70 vs. an industry ratio of 19.10.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: News Headlines , Earnings



More from NASDAQ.com News

Subscribe







NASDAQ.com News
Contributor:

NASDAQ.com News

Market News












Research Brokers before you trade

Want to trade FX?